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Abstract  26 
 27 
HIV and SIV replication in human cells is restricted at early post-entry steps by host inhibitory 28 
factors. We previously described and characterised an early phase restriction of HIV-1 and 2 29 
replication in human cell lines, primary macrophages and PBMCs. The restriction was termed 30 
Lentiviral restriction 2 (Lv2). The viral determinants of Lv2 susceptibility mapped to the HIV-2 31 
Env and CA. We subsequently reported a whole genome siRNA screen for factors involved in to 32 
HIV which identified RNA-associated Early-stage Anti-viral Factor (REAF). Using HIV-2 chimeras 33 
of susceptible and non-susceptible viruses we show here that REAF is a major component of the 34 
previously described Lv2. Further studies of the viral CA demonstrate that the CA mutation I73V 35 
(previously called I207V), a potent determinant for HIV-2, is a weak determinant of 36 
susceptibility for HIV-1. More potent CA determinants for HIV-1 REAF restriction were identified 37 
at P38A, N74D, G89V and G94D.  These results firmly establish that in HIV-1 CA is a strong 38 
determinant of susceptibility to LV2/REAF.  Similar to HIV-2 the HIV-1 Env can rescue sensitive 39 
CAs from restriction. We conclude that REAF is a major component of the previously described 40 
Lv2 restriction. 41 
 42 
 43 
 44 
 45 
 46 
Importance 47 
 48 
Measures taken by the host cell to combat infection drive the evolution of pathogens to 49 
counteract or side step them. The study of such virus-host conflicts can point to possible 50 
weaknesses in the arsenal of viruses and may lead to the rational design of anti-viral agents. 51 
Here we describe our discovery that the host restriction factor REAF fulfils the same criteria 52 
previously used to describe Lentiviral restriction (Lv2). We show that, like HIV-1 CA, the CA of 53 
HIV-1 is a strong determinant of LV2/REAF susceptibility.  We illustrate how HIV counteracts 54 
LV2/REAF by using an envelope with alternative routes of entry into cells.  55 
 56 
 57 
Introduction  58 
 59 
Infection of cells by human and simian immunodeficiency virus (HIV and SIV) is initiated by 60 
binding of the viral envelope (Env) to CD4. Conformational changes in the viral Env expose a site 61 
that can interact with a chemokine receptor, either CXCR4 or CCR5, expressed at the cell 62 
surface of CD4+ T cells and primary macrophages (1, 2). Viruses in general can enter cells 63 
through different routes, either directly at the plasma membrane (PM) or through one of a 64 
number of endocytic pathways (3).  Influenza is a prototypical virus that enters cells through an 65 
endocytic route and requires the acid environment of the late endosome to trigger its fusion 66 
and entry into cells. Since the mechanism of HIV fusion is pH independent (4) it has been widely 67 
assumed that HIV fuses at the PM (5-7). pH independent endocytic entry has recently been 68 
observed (8-15) and is thus a possible mechanism of HIV entry; this however remains a topic of 69 
considerable controversy (16, 17). Regardless of the route, once HIV fuses at the plasma 70 
membrane the conical core is released into the cytoplasm. The viral genomic RNA is reverse 71 
transcribed by the virally encoded RNA/DNA dependent reverse transcriptase (RT), resulting in 72 
virally encoded RNA:DNA, single and double stranded (ss and ds)DNA intermediates. The RNase 73 
H activity of RT degrades the RNA from these hybrids resulting in ssDNA from which the second 74 
DNA strand is synthesised (18, 19). Once reverse transcription is complete the double stranded 75 
proviral DNA is processed for integration into the host cell genome. 76 
 77 
HIV must overcome many cellular barriers to its replication as it journey to the nucleus to 78 
integrate into the host genome (20, 21). Interferon-induced transmembrane proteins (IFITMs) 79 
can inhibit virus-cell membrane fusion (22) and the process of reverse transcription itself is also 80 
vulnerable. Immediately after initiation, members of the Apolipoprotein B mRNA-editing, 81 
enzyme-catalytic, polypeptide-like (APOBEC) family of restriction factors induce deoxycytidine 82 
to deoxyuridine mutations in the nascent DNA (23). Further disabling reverse transcription 83 
SAMHD1 depletes the dNTP substrates required (24). RNA-associated Early-stage Anti-viral 84 
Factor (REAF) was described to inhibit HIV and SIV replication during reverse transcription (25). 85 
REAF is intrinsically expressed and provides an initial line of defence against HIV and SIV 86 
infection. It associates with reverse transcripts; either ssDNA or RNA:DNA hybrids, however the 87 
precise mechanism of its action is not yet understood. A more recently described restriction 88 
factor MX2/MXB inhibits replication at a later stage, suppressing nuclear import and proviral 89 
formation (26-28). Integration is inhibited by the TRIM28 (KAP1)/SETDB1 complex (29). Once 90 
the provirus is integrated the late phase of the replication cycle begins with the production of 91 
viral proteins (30). A plasma membrane located restriction factor tetherin/BST2/CD317, 92 
prevents viruses from leaving the cell at the late budding stage of the life cycle (31).  93 
 94 
The first Lentiviral restriction factor 1 (Lv1) effective against HIV-1 was identified as rhesus 95 
TRIM5α (32, 33). Lv1/TRIM5α is species specific and active against HIV-1 in non-human primate 96 
cells. TRIM5α forms a lattice around the capsid (CA) resulting in premature disassembly of the 97 
conical core (34). It is not known if Lv2 is species specific. It inhibits HIV-1 and 2 during reverse 98 
transcription and susceptibility is determined by the viral CA (35). Lv2 differs from Lv1 in that 99 
the Env is an additional determinant of restriction. Approximately half of HIV-1 and HIV-2 100 
viruses are susceptible to Lv2 (35). Lv3 is a post entry restriction to infection of simian MAGI 101 
cells by HIV-1 and similar to Lv2 is dependent on fusion events at the cell membrane (36). Lv4 102 
restricts nuclear entry of SIV isolates in human cells (37).  A recently described restriction to 103 
HIV-1 induced by TLR 7/8 agonist in human monocytes is termed Lv5 (38). So far the identities 104 
of Lv3, 4 and 5 are unknown. Here we describe the identification of REAF as a potent 105 
component of Lv2. 106 
 107 
To identify components of Lv2 we designed a whole genome siRNA screen (20). HeLa-CD4 cells 108 
were transfected with an siRNA library targeting 19,121 human genes and then challenged with 109 
an HIV-189.6 (MCR) pseudovirus (20). One factor identified was RPRD2 (here called RNA-110 
associated Early-stage Anti-viral Factor; REAF) which we now show fulfils the characteristics 111 
used to define Lv2 (35,38).  112 
 113 
Materials and Methods 114 
 115 
Cells. Buffy coats from seronegative donors were obtained from the National Blood Service 116 
(Brentwood, UK). Donors were anonymous and patient consent was not required. Peripheral 117 
blood mononuclear cells (PBMC) were prepared by density-gradient centrifugation 118 
(Lymphoprep, Axis-Shield). Monocyte-derived macrophages (MDM) were isolated from PBMC 119 
using CD14+ MACS Microbeads (Miltenyi Biotec) and left to differentiate for 5 days in RPMI 120 
1640/10% foetal calf serum (FCS) and 15ng/ml granulocyte macrophage colony stimulating 121 
factor (GM-CSF; Peprotech). HEK 293T, HeLa-CD4, U87-CD4-CXCR4, HeLa EKV and HeLa 122 
EKVΔCPSF6-358 cells and their optimal culture conditions have been described previously (39-123 
42). 124 
Preparation of REAF knockdown cells. The pSUPER RNAi system (pSUPER.retro.puro; 125 
Oligoengine) was used for expression of shRNA in mammalian cells (43, 44). For REAF 126 
knockdown pSUPER.retro.puro(shREAF) was generated by digestion with BglII and HindIII, 127 
annealing of the specific primers and ligation. The shRNA target sequences are shown in upper 128 
case within the primers listed below:  129 
shREAF-BglII: 5’ gatccccCACGTAAGCCCTCAGATGAttcaagagaTCATCTGAGGGCTTACGTGttttta 3’  130 
shREAF-HindIII: 5’ agcttaaaaaCACGTAAGCCCTCAGATGAtctcttgaaTCATCTGAGGGCTTACGTGggg 131 
3’ 132 
The vector was either transfected directly into HeLa-CD4 cells for transient knockdown or used 133 
to generate stable knockdown cell lines. Briefly, retroviruses were produced by co-transfecting 134 
pSUPER.retro.puro(shREAF) with an HIV-1 gag-pol expression vector (p8.91) (45) and pMDG 135 
VSV-G Env into HEK 293T cells. Supernatant containing virus was harvested after 48 hours and 136 
was used to transduce HeLa-CD4 cells under puromycin selection. REAF silencing in transient 137 
and stably knocked down cells was confirmed by Western blot. 138 
 139 
Plasmids and virus production. The infectious molecular clone for HIV-189.6 was obtained from 140 
the Centre for AIDS Research (NIBSC, UK). Infectious full-length and chimeric HIV clones were 141 
prepared by polyethylenimine (PEI; Polysciences) or Lipofectamine 2000 (Invitrogen) 142 
transfection of HEK 293T cells. The virus named in parentheses for each pseudotype denotes 143 
the Env used. 144 
 145 
Production of CA mutant viruses. HIV-1 CA mutants were generated by site directed 146 
mutagenesis (SDM) of the HIV-1NL4.3-derived viral clone pBR-NL43-IRES-eGFP (46) with further 147 
modification to introduce stop codons in the first and third codons of the Env coding sequence. 148 
HIV-1 pseudovirus particles were produced by PEI transfection of HEK 293T cells using a 1:1 149 
molar ratio of viral plasmid to MCR/MCN/VSV-G/NL4.3 Env expression plasmid. 150 
 151 
Western blot. SDS-PAGE separated proteins were detected with the primary rabbit polyclonal 152 
antibody against REAF (Eurogentec) or GAPDH (loading control; Abcam) followed by 153 
horseradish peroxidase-conjugated donkey α-rabbit antibody (GE Healthcare). Protein was 154 
visualised using a chemiluminescence kit (ECL; GE Healthcare). 155 
  156 
siRNA transfection and infection with replication competent virus. HeLa-CD4 cells were 157 
seeded at 2.5×104 cells/well in 24-well plates. siRNA transfection (30nM) was performed using 158 
HiPerfect (QIAGEN) according to the manufacturer’s instructions using the following sequences: 159 
siREAF: 5’ CACGTAAGCCCTCAGATGATA 3’ 160 
siCB:  5’ ACAGCAAATTCCATCGTGT 3’  161 
72 hours after siRNA transfection, cells were challenged with virus for up to 5 hr. Infection was 162 
assessed up to 48 hours by intracellular p24 staining.  163 
 164 
In situ immunostaining for p24 antigen. Infected cells were fixed with cold (-20°C) 165 
methanol:acetone (1:1), washed with PBS then immunostained for p24 using mouse anti-HIV-1 166 
p24 monoclonal antibodies EVA365 and 366 (NIBSC, UK) (1:50) as previously described (47). 167 
Infected cell foci stained blue (regarded as foci of infection (FFU/ml)) and were quantitated by 168 
light microscopy.  169 
 170 
Statistical analysis. The results presented are derived from a minimum of three independent 171 
experiments performed in duplicate at minimum. Differences between two treatments were 172 
tested for statistical significance using unpaired two-tailed t-Tests. * denotes p < 0.05, n.s. not 173 
significant.  174 
 175 
Results 176 
 177 
The HIV-2 molecular determinants of Lv2 restriction were previously mapped using two HIV-2 178 
molecular clones of viruses derived from the same patient, HIV-2MCR and HIV-2MCN, which are 179 
differentially sensitive to Lv2.  A gene swapping approach between the viruses identified the 180 
gag and env genes as critical determinants of Lv2 restriction (39). These chimeric viruses 181 
(shown schematically in Fig. 1A) were tested to determine if they had the same pattern of 182 
susceptibility to REAF. 183 
HeLa-CD4 cells were knocked down for REAF using specific (siREAF) or non-targeting control 184 
siRNA (cyclophilin B, siCB) (Fig. 1B). Fig. 1C shows viral rescue in HeLa-CD4 cells following 185 
treatment with siREAF and compared with cells treated with siCB. Repeat experiments 186 
consistently show, as expected for a virus highly sensitive to Lv2 (39), that the HIV-2MCR virus is 187 
potently rescued in comparison to HIV-2MCN (50 fold vs 10 fold; p = 0.004). When the env and 188 
gag from the restricted HIV-2MCR was inserted in place of the relatively insensitive HIV-2MCN env 189 
and gag (HIV-2MCNmcr env+gag), greater sensitivity of this virus to REAF was observed (66 fold). In 190 
the reciprocal experiment, where the env and gag from HIV-2MCN replaced the HIV-2MCR genes 191 
(HIV-2MCRmcn env+gag), the resulting chimera was only rescued 3 fold (p < 0.001). These results for 192 
susceptibility to REAF are consistent with the Lv2 phenotype previously described (39). A single 193 
point mutation in HIV-2MCR CA at position 73 is known to be a critical determinant of Lv2 194 
restriction (previously labelled position 207). Fig. 1C shows that HIV-2MCR CA I73V is rescued only 195 
12 fold from REAF restriction compared to 50 fold for wild type HIV-2MCR (p = 0.003).   196 
To confirm these results and for further experiments we generated HeLa-CD4 cell lines 197 
permanently expressing shRNA specific for REAF mRNA. Western blot (WB) analysis shows that 198 
the HeLa-CD4-shREAF cells expressed much less REAF protein than the parental HeLa-CD4 cells 199 
(Fig. 1D). The phenotype of knockdown of REAF in this cell line was confirmed using HIV-2MCR 200 
and HIV-2MCR CA I73V. The HIV-2MCR virus was restricted 326 fold compared to 33 fold for the HIV-201 
2MCR CA I73V (Fig. 1E; p = 0.016).  202 
We previously reported that Lv2 was active in HeLa-CD4, human primary PBMC and MDM but 203 
not in U87-CD4-CXCR4 cells (39). REAF mRNA (data not shown) and protein is present in MDM 204 
and to much lower levels in PBMC (Fig. 1F) while WB analysis shows it to be barely detectable in 205 
U87-CD4-CXCR4 (Fig. 1G).  206 
 207 
As previously reported for Lv2 (39) and further demonstrated here, the HIV-2 determinants for 208 
REAF are Env and CA (specifically amino acid 73). We sought to identify the determinants of 209 
REAF restriction for HIV-1. Fig. 2A shows that, compared to HIV-189.6, HIV-1NL4.3 is more resistant 210 
to REAF restriction (3 fold vs 21 fold; p < 0.001). We used HIV-1NL4.3 to further establish if the 211 
equivalent HIV-2 CA mutation 73 plays a role in Lv2/REAF restriction in HIV-1. Using SDM we 212 
generated HIV-1NL4.3 CA I73V. Both wild type and mutant CA were pseudotyped with HIV-2MCR Env 213 
and/or HIV-1NL4.3 Env and tested for their susceptibility to REAF using the HeLa-CD4-shREAF cell 214 
line. Fig. 2B shows that wild type HIV-1NL4.3 CA is only weakly susceptible to REAF when 215 
pseudotyped with HIV-1NL4.3 Env. However when the CA is mutated (HIV-1NL4.3 CA I73V (NL4.3)) the 216 
restriction is more potent but still relatively weak compared to HIV-2 (15 fold, compare to Fig. 217 
1E for HIV-2). The CA I73V was further restricted when pseudotyped with an HIV-2MCR Env (21 218 
fold, p = 0.03), but not with HIV-2MCN Env (16 fold, p = n.s.). Thus CA amino acid 73 and Env are 219 
determinants of Lv2/REAF restriction for both HIV-1 and 2.  220 
 221 
The CA amino acid at position 73 lies in the binding domain of the cleavage and polyadenylation 222 
specific factor 6 (CPSF6) protein (48). This is of particular interest as the adjacent CA mutation 223 
(N74D) has been shown to affect the sensitivity of HIV-1 to depletion of RanBP2, Nup153 and 224 
TNPO3 nuclear pore proteins (49, 50).  225 
N74D is an HIV-1 escape mutant that was generated by passage of HIV-1NL4.3 in cells expressing 226 
an artificially mutated CPSF6-358 that perturbs HIV-1 nuclear entry (50). CPSF6 is a pre-mRNA 227 
processing protein that shuttles between the nucleus and the cytoplasm (51). The mutant form 228 
CPSF6-358 lacks a C-terminal nuclear-targeting arginine/serine (RS)-rich domain and so is 229 
confined to the cytoplasm and restricts HIV-1 before nuclear entry (50, 52, 53). 230 
We tested whether the Lv2/REAF HIV-2 CA determinant I73V was similar to N74D with respect 231 
to resistance to CPSF6-358. Another CA mutation, P38A, which was mutated outside the CPSF6 232 
CA binding region was included as a negative control (54). HeLa-CD4 target cells permanently 233 
expressing the mutant CPSF6-358 (HeLa EKVΔCPSF6-358) or vector alone (HeLa EKV) (42, 48) 234 
were challenged with pseudotypes carrying a mutant or wild type CA. Fig. 2C shows that, as 235 
expected, infection of the pseudotypes with wild type and P38A CA are inhibited (62 and 73 236 
fold respectively). However both CA mutants, HIV-1NL4.3 CA I73V (VSV-G) and HIV-1NL4.3 CA N74D (VSV-237 
G), were resistant to CPSF6-358 (3.3 and 1.6 fold; both p < 0.001).   238 
 239 
Given this similarity in resistance to CPSF6-358 we also sought to determine whether, similar to 240 
I73V, N74D is more susceptible than wild type virus to REAF restriction. HeLa-CD4 and HeLa-241 
CD4-shREAF cells were challenged by pseudotypes with either wild type or mutated CA. Fig. 3A 242 
shows that HIV-1NL4.3 (MCR) is rescued 13 fold. Surprisingly HIV-1NL4.3 CA N74D (MCR) is even more 243 
restricted and is rescued 53 fold (p < 0.001), suggesting CA N74D is a more potent determinant 244 
of REAF restriction in HIV-1 245 
As well as being less sensitive to CPSF6-358, the CA N74D mutation has a more stable conical 246 
core which results in delayed disassembly and reverse transcription (55). It is thought that 247 
optimal disassembly of the conical core is required for successful infection as mutations 248 
interfering with core stability often result in a disturbance of reverse transcription kinetics (54, 249 
56-58). We previously reported that REAF was transiently down modulated shortly after 250 
infection (25). We hypothesised that unstable capsids will prematurely disassemble and expose 251 
reverse transcripts to REAF. The corollary of this is that capsids that disassemble too late will 252 
miss the window of time where REAF is absent. To test this hypothesis that capsid stability was 253 
a determinant of REAF/Lv2 restriction we investigated the REAF susceptibility of CA mutations 254 
with varying CA stability. P38A, in contrast to N74D, is highly unstable (54, 59) while G94D is 255 
unaffected (55). The G89V mutation in the cyclophilin binding loop was chosen because it has 256 
previously been shown to affect sensitivity to host restriction factors  (42, 54, 57, 58). P38A is 257 
also distinct from N74D in that it is sensitive to CPSF6-358 (Fig. 2C). Fig. 3C, D and E show the 258 
infectivity of all three capsid mutants. HIV-1NL4.3 CA P38A (MCR), HIV-1NL4.3 CA G89V (MCR) and HIV-259 
1NL4.3 CA G94D were severely compromised on HeLa-CD4 cells (titre of <500 FFU/ml; compared to 260 
wild type CA, Fig. 3B). However their replication was rescued in the absence of REAF similar to 261 
HIV-1NL4.3 CA N74D (MCR) (Fig. 3F; all p < 0.001). 262 
 263 
We showed above that in addition to CA, HIV-1 Env also confers sensitivity to REAF (Fig. 2B). We 264 
previously determined that HIV-2MCN Env has the ability to overcome Lv2 (35, 39).  If REAF is Lv2 265 
the HIV-2MCN Env would overcome REAF restriction. HeLa-CD4-shREAF cells were challenged 266 
with HIV-1NL4.3 with a wild type CA pseudotyped with HIV-2MCN Env. As expected the wild type 267 
HIV-1NL4.3 CA was only slightly restricted and the HIV-2MCN Env could reduce this to a small but 268 
significant degree (5.6 to 3.1 fold; p = 0.007) (Fig. 4A). In contrast the HIV-1NL4.3 strains carrying 269 
REAF sensitive CA mutations N74D, P38A, G89V and G94V were potently rescued with the HIV-270 
2MCN Env (Fig. 4B-E, all p-values < 0.001) further confirming that REAF and Lv2 are similarly 271 
rescued by viral Env.  272 
 273 
Discussion 274 
Here we show that REAF is a major component of the previously described restriction Lv2 (35, 275 
60, 61) . HIV chimeric viruses and mutants that delineate susceptible and resistant clones 276 
demonstrate that Lv2 and REAF are indistinguishable. Both Lv2 and REAF restriction activity are 277 
molecularly determined by the viral Env and CA. The CA amino acid at position 73 in HIV-2 was 278 
a crucial determinant of Lv2 and confirmed here for REAF (39). The equivalent amino acid at 279 
position 73 also affects HIV-1 susceptibility to REAF. Although the effects of I73V are statistically 280 
significant they are much weaker compared to HIV-2. Indeed, the same amino acid substitution 281 
rendered HIV-2MCN less susceptible but HIV-1NL4.3 more susceptible to REAF. This led us to the 282 
hypothesis that the overall structure or stability of the CA rather than precise molecular 283 
interactions is critical. It has been proposed that disassembly too early prior to localisation at 284 
the nuclear pore would result in exposure to restriction factors and premature termination of 285 
reverse transcription (19, 62-65). Indeed it has been proposed that HIV-1 disassembly involves a 286 
regulated collapse of the conical core which protects viral reverse transcription complexes (66). 287 
Also it has been shown that disassembly occurs within an hour of fusion and is facilitated by 288 
reverse transcription (67-69). We have observed that cellular REAF is reduced within one hour 289 
of viral challenge, but importantly, levels are rapidly replenished an hour later (25). REAF 290 
associates with viral nucleic acid and restricts replication during reverse transcription (25). We 291 
therefore suggested that the temporary reduction in REAF protein level allows viruses to 292 
reverse transcribe in the absence of REAF associated activity. This model is in keeping with the 293 
notion that CA stability is a determinant of REAF associated restriction. We further tested the 294 
hypothesis that CA stability is a determinant of REAF susceptibility using already well 295 
characterised mutants with different CA stabilities.  Compared to I73V (20 fold) more potent 296 
effects (more than 50 fold) were observed with mutants P38A (unstable), N74D (hyperstable) 297 
and G94D (unaffected) (55). Since all these CA mutations result in greater susceptibility to REAF 298 
associated activity despite having divergent CA stabilities we cannot conclude that CA stability is 299 
a major determinant of susceptibility to REAF. Regardless we show that the CA is a strong 300 
determinant of REAF restriction in HIV-1.  Given the multifunctional role of CA in HIV-1 301 
replication (70), understanding the role of CA in susceptibility to REAF associated activity may 302 
shed light on more specific interactions of CA with host cell factors required for efficient 303 
infectivity of HIV.  304 
 305 
It is highly controversial whether or not infectious HIV conical cores enter the cytoplasm after 306 
fusion at the plasma membrane or through an endocytic route (8-17, 35, 60). Our previous 307 
observation of Lv2 suggests that, although either route is possible, infection is more successful 308 
when the virus fuses at the plasma membrane and avoids an endocytic entry pathway (35, 60). 309 
Our results here confirm that, like Lv2, the choice of entry route as determined by the viral Env 310 
is a determinant of susceptibility to REAF associated activity. HIV-1NL4.3 can be rendered 311 
sensitive to REAF if pseudotyped with HIV-2MCR while HIV-2MCN Env does not. These previously 312 
characterised HIV-2 Envs fuse either at the plasma membrane (MCN) or via an endocytic route 313 
(MCR) [35,38]. Furthermore all CA mutants which were rendered highly sensitive to REAF 314 
associated activity were protected when pseudotyped with an MCN Env.  315 
We propose that, similar to Lv2, REAF may be more active against viruses attempting to access 316 
the cytoplasm via an endosome. Therefore, fusion at the plasma membrane is a more efficient 317 
replication pathway. However we cannot eliminate the possibility that some viruses will bypass 318 
REAF associated activity regardless of entry route, for example if they have a conical core 319 
without the sensitivity conferring mutations described here. Future studies that address the 320 
role of Env and CA in determining REAF associated restriction will shed light on these early host 321 
cell interactions in the early life cycle of HIV.  322 
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 515 
Figure legends  516 
 517 
Figure 1 518 
  519 
REAF is an important component of Lv2. A) A schematic representation of the HIV-2 molecular 520 
clones, chimeric viruses and site directed mutagenesis (*) used to map the determinants of 521 
REAF restriction. B) Western blot of HeLa-CD4 cell lysate following REAF siRNA knockdown 522 
compared with non-targeting control (siCB). GAPDH is added as a loading control. C) Titration of 523 
constructs on HeLa-CD4 cells transiently transfected with siREAF showing fold change 524 
compared to cells transfected with siCB control (compared with HIV-2MCR: HIV-2MCN p = 0.004, 525 
HIV-2MCNmcr env+gag p = n.s., HIV-2MCRmcn env+gag p < 0.001, HIV-2MCR CA I73V p = 0.003). D) WB of 526 
knockdown of REAF in HeLa-CD4-shREAF cells compared to HeLa-CD4 cells. GAPDH is added as a 527 
loading control. E) Fold change for HeLa-CD4-shREAF cells infected with HIV-2MCR and HIV-2MCR 528 
CA I73V confirms the Lv2 phenotype in the stable knockdown cells (p = 0.016). F) WB of REAF 529 
levels in MDM and PBMC compared to HeLa-CD4 cells. GAPDH is added as a loading control. G) 530 
WB of REAF levels in U87-CD4-CXCR4 cells compared to HeLa-CD4 cells. GAPDH is added as a 531 
loading control. 532 
 533 
 Figure 2 534 
 535 
The HIV-1 CA determinants of REAF associated restriction are the same as those for HIV-2 and 536 
are in the CPSF6 binding pocket. A) A comparison of the susceptibility of HIV-1NL4.3 and HIV-189.6 537 
following transient knockdown of REAF by siRNA (p < 0.001). B) Mutation of the HIV-1NL4.3 538 
capsid (HIV-1NL4.3 CA I73V (MCR) or HIV-1NL4.3 CA I73V (NL4.3)) renders it susceptible to restriction in 539 
HeLa-CD4-shREAF cells (p = 0.03). C) Fold inhibition of HIV-1NL4.3 (VSV-G) with CA mutants I73V 540 
and N74D (p < 0.001) in the presence of mutant CPSF6-358 compared to vector alone. 541 
 542 
Figure 3 543 
 544 
Mutant capsids are sensitive to REAF restriction. A) Infection of HeLa-CD4-shREAF cells with 545 
HIV-1NL4.3 CA N74D (MCR) renders it susceptible to REAF compared to viral pseudotype with wild 546 
type CA (HIV-1NL4.3 (MCR)) (p < 0.001). B-E) Titres of HIV-1NL4.3 (MCR), HIV-1NL4.3 CA P38A (MCR), 547 
HIV-1NL4.3 CA G89V (MCR) and HIV-1NL4.3 CA G94D (MCR) following challenge of HeLa-CD4 and HeLa-548 
CD4-shREAF cells. F) Fold change for HIV-1NL4.3 CA P38A (MCR), HIV-1NL4.3 CA G89V (MCR) and HIV-549 
1NL4.3 CA G94D (MCR) on HeLa-CD4-shREAF cells compared to wild type CA (HIV-1NL4.3 (MCR)) show 550 
they are also susceptible to REAF (all p <0.001). 551 
 552 
Figure 4 553 
 554 
Viral envelope determines susceptibility to REAF associated restriction. A) Infection of HeLa-555 
CD4-shREAF cells with HIV-1NL4.3 (MCN) decreases sensitivity to REAF associated restriction 556 
compared to HIV-1NL4.3 (MCR) (p = 0.007).  Comparison of HIV-2MCR and HIV-2MCN Env on 557 
pseudotypes carrying B) N74D (p < 0.001), C) P38A (p < 0.001), D) G89V (p < 0.001) and E) G94D 558 
(p = 0.001) CA show HIV-2MCN Env makes these viruses less sensitive to REAF. 559 




